Evidence map›Paper›PMID 42305291›Full record

ArticleArchives of medical science : AMS2026

The relationship between RSUME and VHL/HIF-1α signalling pathway in renal cell carcinoma.

Yuanliang Wang, Xin Wang, Faliang Zhao, Anjian Chen, Tiangcai Liang, Yang Du, Hao Li, Jiang Du, Zifeng Fu, Guobiao Liang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of medical science : AMS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yuanliang WangDepartments of Urology, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Xin WangDepartments of Urology, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Faliang ZhaoDepartments of Urology, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Anjian ChenDepartments of Urology, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Tiangcai LiangDepartments of Urology, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Yang DuDepartments of Urology, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Hao LiDepartments of Urology, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Jiang DuDepartments of Urology, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Zifeng FuDepartments of Urology, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Guobiao LiangDepartments of Urology, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Renal cell carcinoma (RCC) is characterised by loss of the von Hippel-Lindau tumour suppressor gene ( Material and methods: Immunohistochemistry and real-time PCR were applied to detect the expression levels of VHL, HIF-1α, and RSUME in normal renal tissue (control group) and RCC (experimental group). Results: The results revealed that RSUME and HIF-1α were significantly upregulated in RCC tissues compared with normal renal tissues ( Conclusions: These results suggested that upregulated expression of RSUME may be involved in the formation and progression of renal cell carcinoma via interaction with VHL/HIF-1α signalling pathway, and thus RSUME may be a novel potential therapeutic target for renal cell carcinoma.

Indexed as

HIF-1αhuman RWD-containing sumoylation enhancerrenal cell carcinomaVHL

Identifiers

PMID42305291
PMCPMC13266532

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.